ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03336216
Recruitment Status : Recruiting
First Posted : November 8, 2017
Last Update Posted : July 6, 2018
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Condition or disease Intervention/treatment Phase
Advanced Pancreatic Cancer Biological: Cabiralizumab Drug: Nab-paclitaxel Drug: Onivyde Biological: Nivolumab Drug: Fluorouracil Drug: Gemcitabine Drug: Oxaliplatin Drug: Leucovorin Drug: Irinotecan Hydrochloride Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Actual Study Start Date : December 15, 2017
Estimated Primary Completion Date : December 14, 2020
Estimated Study Completion Date : December 15, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Active Comparator: Arm A

Investigator choice of chemotherapy either gemcitabine/nabpaclitaxel (ABRAXANE) or 5-fluorouracil/leucovorin/irinotecan Liposome (ONIVYDE)

ONIVYDE-based regimen can be substituted with FOLFIRI (leucovorin, fluorouracil, irinotecan hydrochloride)

Drug: Nab-paclitaxel
specified does on specified days
Other Name: Abraxane

Drug: Onivyde
specified dose on specified days
Other Name: irinotecan liposome

Drug: Fluorouracil
specified dose on specified days
Other Name: 5-Fluorouracil

Drug: Gemcitabine
specified dose on specified days

Drug: Leucovorin
Specified dose on specified days

Drug: Irinotecan Hydrochloride
Specified dose on specified days

Experimental: Arm B
Cabiralizumab and Nivolumab
Biological: Cabiralizumab
specified dose on specified days
Other Name: BMS-986227, FPA008

Biological: Nivolumab
specified dose on specified days
Other Name: Opdivo, BMS-936558

Experimental: Arm C
cabiralizumab and nivolumab in combination with gemcitabine and abraxane
Biological: Cabiralizumab
specified dose on specified days
Other Name: BMS-986227, FPA008

Drug: Nab-paclitaxel
specified does on specified days
Other Name: Abraxane

Biological: Nivolumab
specified dose on specified days
Other Name: Opdivo, BMS-936558

Drug: Gemcitabine
specified dose on specified days

Experimental: Arm D
cabiralizumab and nivolumab in combination with oxaliplatin/5-Fluorouracil/leucovorin
Biological: Cabiralizumab
specified dose on specified days
Other Name: BMS-986227, FPA008

Biological: Nivolumab
specified dose on specified days
Other Name: Opdivo, BMS-936558

Drug: Fluorouracil
specified dose on specified days
Other Name: 5-Fluorouracil

Drug: Oxaliplatin
specified dose on specified day

Drug: Leucovorin
Specified dose on specified days




Primary Outcome Measures :
  1. Median progression free survival (mPFS) [ Time Frame: Up to 12 months ]
    using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)


Secondary Outcome Measures :
  1. Trough observed serum concentration (Ctrough) [ Time Frame: Approximately 2 years ]
    summary of PK parameters

  2. Objective response rate (ORR) [ Time Frame: Approximately 2 years ]
    assessed per RECIST v1.1

  3. Median duration of response (MDOR) [ Time Frame: Approximately 2 years ]
    assessed per RECIST v1.1

  4. Overall survival rate (OSR) [ Time Frame: Approximately 2 years ]
  5. Incidence of Adverse Events (AE) [ Time Frame: Approximately 2 years ]
  6. Incidence of Serious Adverse Events (SAE) [ Time Frame: Approximately 2 years ]
  7. Incidence of death [ Time Frame: Approximately 2 years ]
  8. Incidence of laboratory abnormalities [ Time Frame: Approximately 2 years ]
  9. Incidence of Adverse Events (AE) leading to discontinuation [ Time Frame: Approximately 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy
  • ECOG Performance status 0-1
  • Adequate organ functions
  • Measurable disease

Exclusion Criteria:

  • Suspected or known CNS metastasis
  • Participants with active, known, or suspected autoimmune disease
  • Uncontrolled or significant cardiovascular disease
  • Prior exposure to selected immune cell-modulating antibody regimens

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03336216


Contacts
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information please email: Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #.

Locations
United States, Arizona
HonorHealth Research Institute Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Erkut Borazanci, Site 0008    480-323-3661      
HonorHealth Not yet recruiting
Scottsdale, Arizona, United States, 85258
Contact: Joyce Schaffer, MSN RN AOCNS         
United States, California
Ucla Medical Center Recruiting
Los Angeles, California, United States, 90095
Contact: Zev Wainberg, Site 0007    310-582-4069      
United States, Colorado
Local Institution Not yet recruiting
Aurora, Colorado, United States, 80045
Contact: Site 0003         
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21287
Contact: Dung Le, Site 0001    410-614-2748      
Sidney Kimmel Comprehensive Cancer Center Not yet recruiting
Baltimore, Maryland, United States, 21287
Contact: Susan Sartorius-Mergenthaler    410-614-3644    Sartosu@jhmi.edu   
United States, Massachusetts
Local Institution Not yet recruiting
Boston, Massachusetts, United States, 02114
Contact: Site 0010         
Local Institution Not yet recruiting
Boston, Massachusetts, United States, 02215
Contact: Site 0015         
United States, Minnesota
Local Institution Not yet recruiting
Rochester, Minnesota, United States, 55905-0001
Contact: Site 0014         
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Andrea Wang-Gillam, Site 0002    314-747-6268      
United States, New York
Laura & Isaac Perlmutter Cancer Ctr at NYU Langone Recruiting
New York, New York, United States, 10016
Contact: Deirdre Cohen, Site 0012         
Local Institution Not yet recruiting
New York, New York, United States, 10065
Contact: Site 0005         
Memorial Sloan Kettering Cancer Center Not yet recruiting
New York, New York, United States, 10065
Contact: Eileen M. O'Reilly    646-888-4182    oreillye@MSKCC.ORG   
United States, Pennsylvania
University Of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Mark O'Hara, Site 0006    215-955-8293      
UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Nathan Bahary, Site 0009    412-235-1324      
United States, Tennessee
Tennessee Oncology, PLLC Recruiting
Nashville, Tennessee, United States, 37203
Contact: Johanna Bendell, Site 0004    615-329-7628      
United States, Texas
Local Institution Not yet recruiting
Dallas, Texas, United States, 75390
Contact: Site 0013         
Md Anderson Recruiting
Houston, Texas, United States, 77030-4009
Contact: Shubham Pant, Site 0011         
Japan
Local Institution Not yet recruiting
Kashiwa-shi, Chiba, Japan, 2778577
Contact: Site 0023         
Local Institution Not yet recruiting
Chuo-ku, Tokyo, Japan, 1040045
Contact: Site 0022         
Taiwan
Local Institution Not yet recruiting
Taipei, Taiwan
Contact: Site 0024         
Sponsors and Collaborators
Bristol-Myers Squibb

Additional Information:
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT03336216     History of Changes
Other Study ID Numbers: CA025-006
First Posted: November 8, 2017    Key Record Dates
Last Update Posted: July 6, 2018
Last Verified: June 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Fluorouracil
Irinotecan
Camptothecin
Oxaliplatin
Nivolumab
Albumin-Bound Paclitaxel
Paclitaxel
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors